Cyclophosphamide treatment of lymphoma during third trimester of pregnancy

John A. Hardin

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Burkitťs lymphoma was diagnosed in a patient during the third trimester of pregnancy. Treatment was high-dose, intermittent cyclophosphamide initially gave a good response which permitted the pregnancy to be carried to term. The infant was normal at birth and had a normal white blood cell count and hematocrit, despite leukopenia in the mother, and he still remains normal at the age of 12 months. Results in this patient and a survey of reported cases in which cyclophosphamide was administered during pregnancy lead to the conclusions that low-dose oral therapy is the least hazardous regimen early in pregnancy while late in pregnancy, large doses administered intravenously may be tolerated without fetal damage.

Original languageEnglish (US)
Pages (from-to)850-851
Number of pages2
JournalObstetrics and Gynecology
Volume39
Issue number6
StatePublished - 1972
Externally publishedYes

Fingerprint

Third Pregnancy Trimester
Cyclophosphamide
Lymphoma
Pregnancy
Leukopenia
Therapeutics
Leukocyte Count
Hematocrit
Mothers
Parturition

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Cyclophosphamide treatment of lymphoma during third trimester of pregnancy. / Hardin, John A.

In: Obstetrics and Gynecology, Vol. 39, No. 6, 1972, p. 850-851.

Research output: Contribution to journalArticle

@article{7c4052810e4f4776953c412d1eb1a3f2,
title = "Cyclophosphamide treatment of lymphoma during third trimester of pregnancy",
abstract = "Burkitťs lymphoma was diagnosed in a patient during the third trimester of pregnancy. Treatment was high-dose, intermittent cyclophosphamide initially gave a good response which permitted the pregnancy to be carried to term. The infant was normal at birth and had a normal white blood cell count and hematocrit, despite leukopenia in the mother, and he still remains normal at the age of 12 months. Results in this patient and a survey of reported cases in which cyclophosphamide was administered during pregnancy lead to the conclusions that low-dose oral therapy is the least hazardous regimen early in pregnancy while late in pregnancy, large doses administered intravenously may be tolerated without fetal damage.",
author = "Hardin, {John A.}",
year = "1972",
language = "English (US)",
volume = "39",
pages = "850--851",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cyclophosphamide treatment of lymphoma during third trimester of pregnancy

AU - Hardin, John A.

PY - 1972

Y1 - 1972

N2 - Burkitťs lymphoma was diagnosed in a patient during the third trimester of pregnancy. Treatment was high-dose, intermittent cyclophosphamide initially gave a good response which permitted the pregnancy to be carried to term. The infant was normal at birth and had a normal white blood cell count and hematocrit, despite leukopenia in the mother, and he still remains normal at the age of 12 months. Results in this patient and a survey of reported cases in which cyclophosphamide was administered during pregnancy lead to the conclusions that low-dose oral therapy is the least hazardous regimen early in pregnancy while late in pregnancy, large doses administered intravenously may be tolerated without fetal damage.

AB - Burkitťs lymphoma was diagnosed in a patient during the third trimester of pregnancy. Treatment was high-dose, intermittent cyclophosphamide initially gave a good response which permitted the pregnancy to be carried to term. The infant was normal at birth and had a normal white blood cell count and hematocrit, despite leukopenia in the mother, and he still remains normal at the age of 12 months. Results in this patient and a survey of reported cases in which cyclophosphamide was administered during pregnancy lead to the conclusions that low-dose oral therapy is the least hazardous regimen early in pregnancy while late in pregnancy, large doses administered intravenously may be tolerated without fetal damage.

UR - http://www.scopus.com/inward/record.url?scp=0015357471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015357471&partnerID=8YFLogxK

M3 - Article

C2 - 5049899

AN - SCOPUS:0015357471

VL - 39

SP - 850

EP - 851

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -